Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures

Implication of an atypical μ-opoid receptor

Phillip K. Peterson, Genya Gekker, Shuxian Hu, James R Lokensgard, Philip S Portoghese, Chun C. Chao

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

Endogneous δ and κ opioid peptides possess a variety of immunomodulatory properties, and κ-opioid receptor ligands recently were shown to suppress the expression of human immunodeficiency virus type 1 (HIV-I) in microglial cells, the resident macrophages of the brain. To determine whether the newly discovered endogenous μ-opioid receptor ligands endomorphin-1 and -2 would affect HIV-1 replication, these peptides were added to acutely infected brain cell cultures. Endomorphin-1 potentiated viral expression, in a bell-shaped dose-response manner with maximal enhancement ≃ 35% at 10-10 M, in both mixed glial/neuronal cell and purified microglial cell cultures. Endomorphin-1's amplifying effect was blocked by pretreatment of brain cells with either the μ-opioid receptor selective antagonist β-funaltrexamine or the G protein inhibitor pertussis toxin. However, the classical μ receptor agonists morphine and DAMGO (Tyr-d-Ala-Gly-N-Me-Phe-Gly-ol) had no effect on viral expression or on endomorphin-1's amplifying effect. Taken together, these findings suggest that in this in vitro model of HIV-1 brain infection, endomorphin-1 potentiates viral expression via activation of an atypical μ-selective opioid receptor. They also provide evidence, for the first time, that an endogenous μ-opioid peptide has neuroimmunomodulatory activity.

Original languageEnglish (US)
Pages (from-to)273-278
Number of pages6
JournalNeuropharmacology
Volume38
Issue number2
DOIs
StatePublished - Feb 1 1999

Fingerprint

HIV-1
Cell Culture Techniques
Opioid Receptors
Brain
Opioid Peptides
phenylalanylglycine
alanylglycine
Ligands
Narcotic Antagonists
mu Opioid Receptor
Pertussis Toxin
GTP-Binding Proteins
Neuroglia
Macrophages
endomorphin 1
Peptides
Infection

Keywords

  • Endogenous opioid peptides
  • Endomorphin
  • Human immunodeficiency virus
  • Neuroimmunomodulation
  • μ-opioid receptors

Cite this

Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures : Implication of an atypical μ-opoid receptor. / Peterson, Phillip K.; Gekker, Genya; Hu, Shuxian; Lokensgard, James R; Portoghese, Philip S; Chao, Chun C.

In: Neuropharmacology, Vol. 38, No. 2, 01.02.1999, p. 273-278.

Research output: Contribution to journalArticle

@article{b08e2346634f4280bacd0bb8ce9f4ec0,
title = "Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures: Implication of an atypical μ-opoid receptor",
abstract = "Endogneous δ and κ opioid peptides possess a variety of immunomodulatory properties, and κ-opioid receptor ligands recently were shown to suppress the expression of human immunodeficiency virus type 1 (HIV-I) in microglial cells, the resident macrophages of the brain. To determine whether the newly discovered endogenous μ-opioid receptor ligands endomorphin-1 and -2 would affect HIV-1 replication, these peptides were added to acutely infected brain cell cultures. Endomorphin-1 potentiated viral expression, in a bell-shaped dose-response manner with maximal enhancement ≃ 35{\%} at 10-10 M, in both mixed glial/neuronal cell and purified microglial cell cultures. Endomorphin-1's amplifying effect was blocked by pretreatment of brain cells with either the μ-opioid receptor selective antagonist β-funaltrexamine or the G protein inhibitor pertussis toxin. However, the classical μ receptor agonists morphine and DAMGO (Tyr-d-Ala-Gly-N-Me-Phe-Gly-ol) had no effect on viral expression or on endomorphin-1's amplifying effect. Taken together, these findings suggest that in this in vitro model of HIV-1 brain infection, endomorphin-1 potentiates viral expression via activation of an atypical μ-selective opioid receptor. They also provide evidence, for the first time, that an endogenous μ-opioid peptide has neuroimmunomodulatory activity.",
keywords = "Endogenous opioid peptides, Endomorphin, Human immunodeficiency virus, Neuroimmunomodulation, μ-opioid receptors",
author = "Peterson, {Phillip K.} and Genya Gekker and Shuxian Hu and Lokensgard, {James R} and Portoghese, {Philip S} and Chao, {Chun C.}",
year = "1999",
month = "2",
day = "1",
doi = "10.1016/S0028-3908(98)00167-1",
language = "English (US)",
volume = "38",
pages = "273--278",
journal = "Neuropharmacology",
issn = "0028-3908",
publisher = "Elsevier Limited",
number = "2",

}

TY - JOUR

T1 - Endomorphin-1 potentiates HIV-1 expression in human brain cell cultures

T2 - Implication of an atypical μ-opoid receptor

AU - Peterson, Phillip K.

AU - Gekker, Genya

AU - Hu, Shuxian

AU - Lokensgard, James R

AU - Portoghese, Philip S

AU - Chao, Chun C.

PY - 1999/2/1

Y1 - 1999/2/1

N2 - Endogneous δ and κ opioid peptides possess a variety of immunomodulatory properties, and κ-opioid receptor ligands recently were shown to suppress the expression of human immunodeficiency virus type 1 (HIV-I) in microglial cells, the resident macrophages of the brain. To determine whether the newly discovered endogenous μ-opioid receptor ligands endomorphin-1 and -2 would affect HIV-1 replication, these peptides were added to acutely infected brain cell cultures. Endomorphin-1 potentiated viral expression, in a bell-shaped dose-response manner with maximal enhancement ≃ 35% at 10-10 M, in both mixed glial/neuronal cell and purified microglial cell cultures. Endomorphin-1's amplifying effect was blocked by pretreatment of brain cells with either the μ-opioid receptor selective antagonist β-funaltrexamine or the G protein inhibitor pertussis toxin. However, the classical μ receptor agonists morphine and DAMGO (Tyr-d-Ala-Gly-N-Me-Phe-Gly-ol) had no effect on viral expression or on endomorphin-1's amplifying effect. Taken together, these findings suggest that in this in vitro model of HIV-1 brain infection, endomorphin-1 potentiates viral expression via activation of an atypical μ-selective opioid receptor. They also provide evidence, for the first time, that an endogenous μ-opioid peptide has neuroimmunomodulatory activity.

AB - Endogneous δ and κ opioid peptides possess a variety of immunomodulatory properties, and κ-opioid receptor ligands recently were shown to suppress the expression of human immunodeficiency virus type 1 (HIV-I) in microglial cells, the resident macrophages of the brain. To determine whether the newly discovered endogenous μ-opioid receptor ligands endomorphin-1 and -2 would affect HIV-1 replication, these peptides were added to acutely infected brain cell cultures. Endomorphin-1 potentiated viral expression, in a bell-shaped dose-response manner with maximal enhancement ≃ 35% at 10-10 M, in both mixed glial/neuronal cell and purified microglial cell cultures. Endomorphin-1's amplifying effect was blocked by pretreatment of brain cells with either the μ-opioid receptor selective antagonist β-funaltrexamine or the G protein inhibitor pertussis toxin. However, the classical μ receptor agonists morphine and DAMGO (Tyr-d-Ala-Gly-N-Me-Phe-Gly-ol) had no effect on viral expression or on endomorphin-1's amplifying effect. Taken together, these findings suggest that in this in vitro model of HIV-1 brain infection, endomorphin-1 potentiates viral expression via activation of an atypical μ-selective opioid receptor. They also provide evidence, for the first time, that an endogenous μ-opioid peptide has neuroimmunomodulatory activity.

KW - Endogenous opioid peptides

KW - Endomorphin

KW - Human immunodeficiency virus

KW - Neuroimmunomodulation

KW - μ-opioid receptors

UR - http://www.scopus.com/inward/record.url?scp=0032968784&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0032968784&partnerID=8YFLogxK

U2 - 10.1016/S0028-3908(98)00167-1

DO - 10.1016/S0028-3908(98)00167-1

M3 - Article

VL - 38

SP - 273

EP - 278

JO - Neuropharmacology

JF - Neuropharmacology

SN - 0028-3908

IS - 2

ER -